
    
      This is a Phase 1/2 open-label, multicenter study, evaluating the safety, tolerability,
      efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN-c3 alone and in combination with
      other drugs. This study consists of Phase 1 and Phase 2 components in participants with solid
      tumors.
    
  